Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EBITDA (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of EBITDA data on record, last reported at -$26.6 million in Q3 2025.

  • For Q3 2025, EBITDA fell 22.02% year-over-year to -$26.6 million; the TTM value through Sep 2025 reached -$92.4 million, down 25.9%, while the annual FY2024 figure was -$83.7 million, 26.83% down from the prior year.
  • EBITDA reached -$26.6 million in Q3 2025 per NWBO's latest filing, down from -$19.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$12.3 million in Q1 2022 and bottomed at -$26.6 million in Q3 2025.
  • Average EBITDA over 5 years is -$18.5 million, with a median of -$18.3 million recorded in 2024.
  • Peak YoY movement for EBITDA: tumbled 149.84% in 2021, then surged 37.22% in 2022.
  • A 5-year view of EBITDA shows it stood at -$12.4 million in 2021, then plummeted by 46.51% to -$18.2 million in 2022, then increased by 16.7% to -$15.1 million in 2023, then crashed by 67.9% to -$25.4 million in 2024, then fell by 4.43% to -$26.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$26.6 million in Q3 2025, -$19.2 million in Q2 2025, and -$21.3 million in Q1 2025.